Helmuth Van Es
 Founder, CSO
 pharmaceutical and biotechnology
Audion Therapeutics
Netherlands
Biography
Dr. Helmuth van Es has been responsible for the creation of a number of biotechnology companies. He is co-founder of Galapagos where he has held various R & D positions including Head of Science at Galapagos where he and his team developed a powerful target discovery and validation RNAi platform and applied this to a range of disease areas such as allergy, osteoporosis, osteoarthritis, rheumatoid arthritis, Alzheimer and cystic fibrosis. His track-record includes international drug discovery and development management of start-up and mid-sized companies. He currently serves on the board of Antabio and Hifibio an MIT, Broad, Harvard and ESPCI spinout developing a microfluidics platform for the discovery of therapeutic biologics. In 2015 he co-founded Citryll an antibody drug development company targeting neutrophil extracellular traps (NETosis) for treatment of SLE and other diseases. He received his PhD in medicine from the University of Amsterdam and did postdoctoral research at McGill University in Montréal.
Research Interest
pharmaceutical and biotechnology
